Innovative Phase I/II Studies

Once children and adolescents suffer a disease relapse, despite first-line therapy and intensive pre-treatment, their chances of recovery are often limited ̶  especially in the case of solid tumors or brain tumors. Thanks to far-reaching developments in molecular genetic analysis and a large number of new so-called targeted drugs and immunotherapeutic approaches, we are confident to better help these children in the near future.

Platzhalter Bild KiTZ

KiTZ Clinical Trial Unit (ZIPO)

Head: Prof. Dr. med. Olaf Witt
Deputy head: Prof. Dr. med. Stefan Pfister

Im Neuenheimer Feld 430
D-69120 Heidelberg

Current studies on individualized therapies